2C-G-3

2C-G-3 is a psychedelic drug of the 2C family. It was first synthesized by Alexander Shulgin, and later reported in his book PiHKAL: A Chemical Love Story. Shulgin classified 2C-G-3 as a member of the "magical half-dozen" of psychedelic substances.

History

2C-G-3 was first synthesized by Alexander Shulgin in the late 20th century. Shulgin's work on the 2C family of drugs was groundbreaking, and he is often credited with popularizing these substances in the scientific and recreational communities.

Chemistry

2C-G-3 is a phenethylamine, a class of compounds that includes many psychoactive drugs. Its full chemical name is 2,5-dimethoxy-3,4-dimethylamphetamine. It is structurally similar to other 2C drugs, but has a longer duration of action due to the presence of two methyl groups on the 3 and 4 positions of the phenyl ring.

Effects

The effects of 2C-G-3 are similar to other 2C drugs, but it is often described as being more introspective and less intense. Users report a range of effects, including visual hallucinations, enhanced sensory perception, and altered thought patterns. The duration of effects can last up to 20 hours, significantly longer than many other psychedelics.

Legal Status

The legal status of 2C-G-3 varies by country. In the United States, it is classified as a Schedule I drug under the Controlled Substances Act, making it illegal to manufacture, distribute, or possess. Other countries have similar laws, although enforcement varies.

Safety

As with all psychedelic substances, 2C-G-3 should be used with caution. Potential risks include psychological distress, physical discomfort, and in rare cases, serious medical emergencies. It is recommended that users have a sober trip sitter present and start with a low dose.

See Also

• 2C-G
• 2C-B
• 2C-I
• 2C-E
• 2C-T-2
• 2C-T-7

2C-G-3 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski